Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III HEEALING 2 study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD).

Next Previous
Trial Profile

A Phase III HEEALING 2 study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD).

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaprazan-glurate (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Registrational; Therapeutic Use
  • Acronyms HEEALING 2

Most Recent Events

  • 30 Oct 2025 New trial record
  • 29 Aug 2025 According to the Cinclus Pharma Media Release, company plans to extend development to the US through the second healing study, HEEALING 2, which will also evaluate maintenance therapy. This study is expected to begin as planned following the topline results of HEEALING 1.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top